Another phase III trial (NCT03199885) is investigating paclitaxel with trastuzumab, pertuzumab, and atezolizumab or placebo in the first line metastatic setting, with the goal of establishing a role for ICIs in a/m HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.